Ciliatoside A
Ciliatoside A is a naturally bioactive compound that exhibits significant anti-inflammatory, antiviral, and neuroprotective activities. Ciliatoside A serves as a mitophagy inducer and NLRP3 inflammasome inhibitor, activating AMPK, SIRT1, and the PINK1/Parkin axis, and inhibiting pyroptosis and apoptosis. Ciliatoside A promotes autophagic flux, autophagosome-lysosome fusion, mTOR inhibition, and p62-dependent HBc degradation; reduces Aβ aggregation, plaque deposition, microglial/astrocyte activation, and bacterial load; and maintains neuronal integrity, mitochondrial membrane potential, and ATP production. Ciliatoside A is used in research on Alzheimer's disease, Klebsiella pneumoniae-induced pneumonia, hepatitis B virus infection, and inflammation.
For research use only. We do not sell to patients.
- CAS No.: 303084-57-3
- Formula: C36H40O19
- Molecular Weight:776.70
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All AMPK Isoforms
More
Biological Activity
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HepG2 2.2.15 | CC50 |
200 μM
|
Cytotoxicity against human HepG2.2.15 cells incubated for 72 h assessed by MTT, CCK-8, Alamar Blue, and flow cytometric apoptosis assays, with CC50 greater than 200 μM.
Cytotoxicity against human HepG2.2.15 cells incubated for 72 h assessed by MTT, CCK-8, Alamar Blue, and flow cytometric apoptosis assays, with CC50 greater than 200 μM.
|
36496141 |
| HepG2 | CC50 |
200 μM
|
Cytotoxicity against human HepG2 cells incubated for 72 h assessed by MTT, CCK-8, Alamar Blue, and flow cytometric apoptosis assays, with CC50 greater than 200 μM.
Cytotoxicity against human HepG2 cells incubated for 72 h assessed by MTT, CCK-8, Alamar Blue, and flow cytometric apoptosis assays, with CC50 greater than 200 μM.
|
36496141 |
| Huh-7 | CC50 |
200 μM
|
Cytotoxicity against human Huh-7 cells incubated for 72 h assessed by MTT, CCK-8, Alamar Blue, and flow cytometric apoptosis assays, with CC50 greater than 200 μM.
Cytotoxicity against human Huh-7 cells incubated for 72 h assessed by MTT, CCK-8, Alamar Blue, and flow cytometric apoptosis assays, with CC50 greater than 200 μM.
|
36496141 |
| RAW264.7 | IC50 |
27.1 μM
|
Inhibition of lipopolysaccharide-induced nitrite accumulation in RAW 264.7 mouse macrophage-like cells, with 1 h pretreatment prior to LPS stimulation and total LPS incubation of 24 h, measured via Griess reaction with absorbance read at 550 nm.
Inhibition of lipopolysaccharide-induced nitrite accumulation in RAW 264.7 mouse macrophage-like cells, with 1 h pretreatment prior to LPS stimulation and total LPS incubation of 24 h, measured via Griess reaction with absorbance read at 550 nm.
|
11087610 |
In Vitro
Ciliatoside A (2.5-10 µM; 12 h) effectively inhibits NLRP3 inflammasome activation and suppresses pyroptosis in LPS (HY-D1056)/Nigericin (Nig) (HY-127019)-stimulated BV-2 microglial cells[1].
Ciliatoside A (10 µM; 12 h) effectively attenuates H2O2-induced oxidative stress, mitochondrial dysfunction, and cell death in BV-2 microglial cells[1].
Ciliatoside A (2.5-10 µM; 6-24 h) activates autophagy and mitophagy in BV-2 microglial cells in a dose- and time-dependent manner through activation of AMPK/ULK1 and PINK1/Parkin signaling pathways, and reverses LPS/Nig-induced mitophagy impairment[1].
Ciliatoside A (0.6-160 μM; 24 h) shows no cytotoxicity in A549 cells at concentrations up to 10 μM, but decreases cell viability at concentrations of 20 μM and higher after 24 h[2].
Ciliatoside A (2.5-10 μM; 24 h) inhibits the expression of KP resistance genes in Klebsiella pneumoniae (KP) bacteria and KP-infected A549 cells[2].
Ciliatoside A (2.5-10 μM; 24 h) protects A549 cells against KP-induced cytotoxicity, restoring cell viability and normal morphology[2].
Ciliatoside A (2.5-10 μM; 24 h) activates the SIRT1/PINK1/Parkin pathway in KP-infected A549 cells[2].
Ciliatoside A (2.5-10 μM; 24 h) attenuates KP-induced mitochondrial damage and oxidative stress in A549 cells by reducing mtROS, restoring MMP and ATP production, and modulating SOD/MDA levels[2].
Ciliatoside A (2.5-10 μM; 24 h) promotes autophagy and restores impaired autophagic flux in KP-infected A549 cells, reduces p62 accumulation, and simultaneously increases LC3-II levels and the number of autophagosomes[2].
Ciliatoside A (2.5-10 μM; 24 h) inhibits KP-induced apoptosis and NLRP3 inflammasome-mediated inflammatory cell death in A549 cells, reducing pro-inflammatory cytokine release and cell death[2].
Ciliatoside A (0-50 μM; 3 days) potently inhibits secreted HBsAg in HBV-infected HepG2-NTCP cells and primary human hepatocytes, with EC50 values of 5.13 μM and 3.36 μM, respectively, without impairing the overall secretory function of the cells[4].
Ciliatoside A (2.5-5 μM; 3-9 days) reduces intracellular HBsAg, secreted HBsAg, HBV RNA, and capsid-derived DNA in HBV-infected HepG2-NTCP cells in a time-dependent manner[4].
Ciliatoside A (1-10 μM; 9 days) inhibits HBV cccDNA transcription, leading to dose-dependent reductions in HBV RNA, HBsAg, and capsid-derived DNA in HBV-infected HepG2-NTCP cells and primary human hepatocytes, without altering cccDNA levels or HBV RNA stability[4].
Ciliatoside A (2.5-5 μM; 3-6 days) induces autophagic flux and autolysosome formation in both HBV-infected and uninfected HepG2-NTCP cells, with a stronger late-stage autophagic response observed in HBV-infected cells[4].
Ciliatoside A (5 μM) enhances the interaction between HBc and the autophagy cargo receptor p62 and accelerates the degradation of HBc protein in Huh-7 cells and HBV-infected HepG2-NTCP cells[4].
Ciliatoside A (0.5-10 μM; 6 days) activates the AMPK-ULK1-mTOR autophagy pathway in a dose-dependent manner in HBV-infected HepG2-NTCP cells, and its anti-HBV effect depends on AMPK activation[4].
Ciliatoside A (3-30 μM; pretreatment for 1 h before LPS stimulation; total LPS incubation time of 24 h) potently inhibits LPS-induced nitrite accumulation in RAW 264.7 mouse macrophage-like cells in a concentration-dependent manner, with an IC50 of 27.1 μM[5].
Ciliatoside A (10-30 μM; 1 h pretreatment prior to LPS stimulation; total LPS incubation 24 h) exhibits weak inhibitory activity against nitrite accumulation in LPS/IFN-γ-stimulated N9 mouse microglial cells, with an inhibition rate of 26.1% at 30 μM[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:BV-2 microglial cells
-
Concentration:2.5, 5, 10 µM (dose-response for LC3 Western blot and GFP-LC3 puncta); 10 µM (time-course and Mito-QC experiments)
-
Incubation Time:24 h (LC3 Western blot and GFP-LC3 puncta); 6, 12, 24 h (time-course); 12 h (pretreatment before LPS/Nig in Mito-QC experiments)
-
Result:Induced a notable and dose-dependent elevation in GFP-LC3 puncta formation in BV-2 cells.
Elevated LC3-II accumulation with both dose- and time-dependent increases in LC3-I to LC3-II conversion as shown by Western blot analysis.
Augmented autophagic flux at 6, 12, and 24 h as confirmed by the ptfLC3 assay.
Further increased GFP-LC3 puncta and LC3-II levels when co-treated with bafilomycin A1, confirming autophagy activation rather than blockade of autophagosome degradation.
Effectively reversed the impaired autophagic flux caused by LPS/Nig in LPS/Nig-stimulated BV-2 cells transfected with ptfLC3.
Enhanced mitophagy and reversed LPS/Nig-induced mitophagy impairment in BV-2 cells transfected with the Mito-QC plasmid at 10 µM.
-
Cell Line:BV-2 microglial cells
-
Concentration:2.5, 5, 10 µM (Western blotting; co-treatment with CC or AC220 (HY-13001) for GFP-LC3 assay)
-
Incubation Time:24 h (Western blotting; GFP-LC3 assay)
-
Result:Increased phosphorylation of AMPK and ULK1, while mTOR phosphorylation levels remained unchanged.
Induced a dose-dependent increase in PINK1 expression and Parkin phosphorylation.
Induced GFP-LC3 puncta formation that was attenuated by co-treatment with the AMPK inhibitor CC or the Parkin inhibitor AC220, indicating that both AMPK and PINK1/Parkin activation are essential for Ciliatoside A-induced autophagy.
-
Cell Line:A549 human lung cancer cells
-
Concentration:0.6, 1.25, 2.5, 5, 10, 20, 40, 80, 160 μM
-
Incubation Time:24 h
-
Result:Showed no considerable impact on A549 cell viability at concentrations of 0.6-10 μM.
Significantly reduced A549 cell viability at concentrations of 20, 40, 80, and 160 μM.
-
Cell Line:Klebsiella pneumoniae (KP)-infected A549 cells and KP bacteria
-
Concentration:2.5, 5, 10 μM (added after 24 h KP infection)
-
Incubation Time:24 h
-
Result:Effectively downregulated RmpA, Acr AB, bla OXA-48, and TEM mRNA levels in both KP bacteria and KP-infected A549 cells.
-
Cell Line:KP-infected A549 cells
-
Concentration:2.5, 5, 10 μM (added after 24 h KP infection)
-
Incubation Time:24 h
-
Result:Reversed KP-induced A549 cell swelling and irregular deformation, restoring normal cell size and clear intercellular boundaries.
Effectively reversed KP-induced reduction in A549 cell viability and significantly improved cell viability.
-
Cell Line:KP-infected A549 cells
-
Concentration:2.5, 5, 10 μM (added after 24 h KP infection)
-
Incubation Time:24 h
-
Result:Further increased autophagosome numbers and significantly alleviated KP-induced mitochondrial structural damage (swelling, cristae disruption) as observed by transmission electron microscopy.
Markedly reduced p62 protein levels while further increasing LC3 protein levels in KP-infected cells as measured by Western blot.
Further amplified the KP-induced increase in GFP-LC3 spots as shown by GFP-LC3 spot formation assay.
Effectively restored KP-blocked autophagy flow and promoted the degradation of autophagic substrates as revealed by GFP-mRFP-LC3 dual-fluorescence experiments.
-
Cell Line:KP-infected A549 cells
-
Concentration:2.5, 5, 10 μM (added after 24 h KP infection)
-
Incubation Time:24 h
-
Result:Markedly reduced the KP-induced apoptosis rate in A549 cells.
Effectively reversed KP-induced BAX upregulation and BCL-2 downregulation.
Effectively suppressed KP-induced release of pro-inflammatory cytokines IL-1β, TNF-α, and IL-6.
Markedly reduced NLRP3 fluorescence intensity and downregulated NLRP3, ASC, and Cleaved-IL-1β/IL-1β protein levels, confirming inhibition of NLRP3 inflammasome activation.
Effectively suppressed the KP-induced increase in PI/Hoechst fluorescence intensity, indicating reduced inflammatory cell death.
-
Cell Line:HBV-infected HepG2-NTCP cells and primary human hepatocytes (PHHs)
-
Concentration:0, 0.39, 0.78, 1.6, 3.1, 6.25, 12.5, 25, 50 μM
-
Incubation Time:3 days
-
Result:Decreased secreted HBsAg levels in a dose-dependent manner in both HBV-infected cell models.
Had an EC50 for HBsAg inhibition of 5.13 μM in HepG2-NTCP cells and 3.36 μM in PHHs, corresponding to selectivity indices greater than 38.99 and 59.52 respectively.
Did not affect albumin or apolipoprotein B secretion even at 50 μM, ruling out a general blockade of cellular secretion pathways.
In Vivo
Ciliatoside A (50-200 μM; administered in nematode growth medium; L3/L4 stage) exerts neuroprotective effects in transgenic C. elegans AD models by reducing Aβ aggregation, decreasing oxidative stress, and enhancing autophagy and mitophagy[1].
Ciliatoside A (2 mg/kg; i.p.; once daily; 2 days) alleviates Klebsiella pneumoniae-induced pneumonia in mice by activating the SIRT1/PINK1/Parkin pathway, reducing pulmonary edema, inflammatory cell infiltration, apoptosis, and bacterial load[2].
Ciliatoside A (0.5 mg/kg; i.p.; every 2 days; 20 days) reduces serum HBsAg by 174.3 IU/mL and serum HBV DNA by 2.15 log10 in an HBV recombinant-cccDNA mouse model, without affecting cccDNA levels and via AMPK-mediated autophagy[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:3xTg-AD (male; 6 months of age)[1]
-
Dosage:0.5 mg/kg; 1 mg/kg; 2 mg/kg
-
Administration:i.p.
-
Result:Reduced total swimming distance and shortened escape latency over 6 training days in the Morris Water Maze test, while average swimming speed remained unchanged.
Reduced Aβ plaque deposition in the hippocampal CA3 region.
Decreased microglial activation (Iba1) and astrocyte activation (GFAP) in the hippocampal CA3, CA1, and dentate gyrus regions.
Preserved neuronal integrity, as indicated by increased numbers of NeuN-positive cells in the hippocampus.
Increased co-localization of LC3 with NLRP3 in the cerebral cortex.
Increased PINK1 expression alongside decreased Iba1 expression in the hippocampus.
-
Animal Model:Multiple transgenic (CL4176, CL2006, CL2331, CL2122, CL2355, DA2123, BC12921, IR1631)[1]
-
Dosage:50 μM; 100 μM; 150 μM; 200 μM
-
Administration:administered in nematode growth medium; L3/L4 stage
-
Result:Dose-dependently reduced Aβ-induced paralysis in CL4176 worms.
Prolonged lifespan in CL2006 worms.
Substantially reduced Aβ aggregation in both CL4176 and CL2331 worms.
Improved movement rates in CL2122 and CL2355 strains.
Significantly decreased ROS levels in CL4176 worms.
Enhanced autophagic activity in DA2123 worms, as shown by increased GFP::LGG-1 puncta formation and elevated PE-GFP::LGG-1 expression.
Reduced GFP::p62 expression in BC12921 worms, indicating enhanced autophagic flux.
Decreased the GFP/DsRed ratio in IR1631 worms, indicating enhanced mitophagy.
-
Animal Model:C57BL/6 (6 weeks old; 15-18 g; both sexes)[2]
-
Dosage:2 mg/kg
-
Administration:i.p.; once daily; 2 days
-
Result:Increased SIRT1, PINK1, and Parkin protein levels in mouse lung tissue.
Reduced the lung wet/dry weight ratio.
Alleviated KP-induced pulmonary pathological damage including alveolar septal edema, thickened alveolar walls, and inflammatory cell infiltration.
Decreased the proportion of TUNEL-positive cells in lung tissue.
Lowered total protein levels in bronchoalveolar lavage fluid.
Reduced IL-1β, IL-6, and TNF-α levels in BALF.
Decreased neutrophil counts in lung tissue.
Reduced myeloperoxidase activity.
Reduced KP bacterial load in lung tissue.
-
Animal Model:Alb-cre transgenic (male; 4-5 weeks of age; HBV recombinant-cccDNA model via hydrodynamic injection of 4 μg precursor plasmid rcccDNA)[4]
-
Dosage:0.5 mg/kg
-
Administration:i.p.; every 2 days; 20 days
-
Result:Reduced serum HBsAg by 174.3 IU/mL compared with the vehicle group.
Reduced serum HBV DNA by 2.15 log10 compared with the vehicle group.
Potently decreased intrahepatic total HBV RNAs, intrahepatic 3.5-kb RNA, intrahepatic HBV DNA, and intrahepatic HBsAg protein levels.
Did not affect intrahepatic cccDNA levels.
Strongly elevated LC3 and Beclin-1 levels in liver tissue.
Increased levels of phosphorylated AMPK and ULK1 in liver tissue.
Reduced levels of phosphorylated mTOR in liver tissue.
Chemical Information
-
CAS No. 303084-57-3
-
Molecular Weight 776.70
-
Formula C36H40O19
-
SMILES
O=C1C2=C(C=3C(C(O[C@H]4[C@H](O[C@H]5[C@H](O)[C@@H](O)[C@@H](O)CO5)[C@](CO[C@H]6[C@H](O)[C@@H](O)[C@H](O)CO6)(O)CO4)=C2CO1)=CC(OC)=C(OC)C3)C=7C=C8C(=CC7)OCO8
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
-
Mitochondrial membrane-potential fluorescent assay
Mitochondrial membrane potential fluorescent assays estimate ΔΨm in living cells using lipophilic cationic dyes such as TMRM, TMRE, rhodamine 123, and JC-1, which accumulate in mitochondria according to membrane polarization; loss of signal after FCCP or CCCP treatment is interpreted as mitochondrial depolarization. TMRM/TMRE and rhodamine 123 are commonly used for semi-quantitative live-cell microscopy or flow cytometry, while JC-1 can report a shift from red aggregate fluorescence to green monomer fluorescence during depolarization; interpretation requires controls because dye concentration, quenching mode, cell type, dye efflux, and mitochondrial mass can affect fluorescence independently of ΔΨm.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Alzheimer’s Disease Modeling
Alzheimer’s Disease (AD) is a neurodegenerative disorder characterized by a progressive decline in cognitive functions and loss of specific types of neurons and synapses. Alzheimer's symptoms can be simulated in mice by injecting drugs (such as Aβ) or genetically modified.
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Fluorescent plasma-membrane potential dye assay
Fluorescent plasma-membrane potential dye assays measure changes in cell membrane potential using voltage-sensitive dyes whose fluorescence changes when cells depolarize or hyperpolarize. Anionic bis-oxonol dyes such as DiBAC4(3) enter depolarized cells more readily and show increased fluorescence after intracellular binding, while hyperpolarization reduces dye accumulation and fluorescence. FMP/FLIPR membrane-potential dyes are used for faster, homogeneous microplate assays of ion-channel or receptor-mediated membrane-potential changes.
-
Autophagy
Autophagy is a process in which eukaryotic cells use lysosomes to degrade their own cytoplasmic proteins and damaged organelles under the regulation of autophagy related gene (Atg). Microtubule-associated proteins light chain 3 (LC3) is recognized as autophagy marker, which transfers from cytoplasmic LC3 (LC3-I) to membrane type (LC3-II). LC3-II/I ratio could be detected by Western Blot and fluorescence microscopy.
-
Mitochondrial membrane-potential and mitochondrial mass staining
Mitochondrial membrane potential staining measures the electrochemical polarization across the mitochondrial inner membrane in live cells using lipophilic cationic fluorescent probes; early rhodamine-based work showed that selective mitochondrial dye accumulation is lost when the mitochondrial transmembrane potential is dissipated. JC-1 reports mitochondrial polarization by shifting from green monomer fluorescence to red J-aggregate fluorescence as dye concentration increases within energized mitochondria; therefore, the red/green fluorescence ratio is used as a relative readout of mitochondrial membrane potential. TMRE or TMRM staining provides a single-channel relative readout because these cationic rhodamine esters accumulate in polarized mitochondria, and lower fluorescence indicates reduced mitochondrial polarization when acquisition and dye-loading conditions are controlled. Mitochondrial mass staining is commonly performed with MitoTracker Green FM or related MitoTracker dyes as
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Lysosome and acidic-vesicle live-cell staining
Lysosome and acidic-vesicle live-cell staining detects acidic intracellular compartments by using membrane-permeant acidotropic probes that accumulate in low-pH vesicles, including lysosomes, late endosomes, autolysosomes, and acidic phagosomes. LysoTracker staining is commonly used as an intensity-based readout of acidic lysosomal compartment abundance or enlargement, while acridine orange produces green fluorescence in less concentrated compartments and red fluorescence after concentration-dependent accumulation in acidic vesicular organelles. Loss or reduction of acridine-orange red signal can be used as a readout of lysosomal membrane permeabilization or reduced acidic-vesicle integrity. This protocol is designed for live cultured cells and can be adapted for fluorescence microscopy, high-content imaging, plate-reader readout, or flow cytometry when the selected literature supports the readout. Because these dyes report acidotropic accumulation rather than lysosome identity alone,
-
Mitophagy Solutions
Mitophagy is the selective autophagic degradation of mitochondria and functions as a mitochondrial quality-control pathway that removes damaged, depolarized, excess, or developmentally programmed mitochondria. The pathway links mitochondrial damage recognition, autophagosome recruitment, lysosomal delivery, and mitochondrial turnover to phenotypes such as mitochondrial homeostasis, oxidative-stress control, metabolic remodeling, differentiation, and neurodegeneration-related mitochondrial fidelity. The best-characterized damage-induced pathway is the PINK1-Parkin axis. Parkin is recruited selectively to impaired mitochondria and promotes their autophagic elimination, while mitochondrial depolarization stabilizes PINK1 on damaged mitochondria, recruits Parkin, and activates Parkin-dependent mitophagy. PINK1 also phosphorylates ubiquitin to activate Parkin E3 ubiquitin ligase activity, and PINK1-driven ubiquitin phosphorylation creates a feed-forward signal for recruiting autophagy machi
-
Macroautophagy Solutions
Macroautophagy is a conserved lysosome-dependent degradation pathway in which cytoplasmic material is sequestered into double-membrane autophagosomes and delivered to lysosomes for degradation and recycling. The pathway supports cellular homeostasis during nutrient limitation, organelle stress, protein-aggregate accumulation, infection, differentiation, and tissue remodeling by coupling cargo sequestration, autophagosome maturation, lysosomal fusion, and degradation of cargo-derived macromolecules. The core molecular sequence includes initiation by nutrient- and stress-regulated autophagy machinery, autophagosome nucleation, LC3/ATG8-family conjugation to autophagosomal membranes, cargo selection through receptors such as SQSTM1/p62, autophagosome-lysosome fusion, and lysosomal degradation. LC3 was identified as a mammalian homolog of yeast Atg8 that localizes to autophagosomal membranes after processing, and p62/SQSTM1 was shown to connect ubiquitinated cargo with autophagic degradati
-
Pyroptosis Solutions
Pyroptosis is a lytic inflammatory cell-death pathway executed by gasdermin pores, most classically through inflammasome-mediated activation of caspase-1, cleavage of gasdermin D, membrane pore formation, LDH release, and secretion of IL-1β and IL-18. The canonical pathway is commonly modeled by priming cells with an inflammatory signal such as LPS to induce pro-IL-1β and inflammasome components, followed by an activation signal such as ATP or nigericin to activate NLRP3, ASC speck formation, caspase-1 cleavage, GSDMD cleavage, cytokine release, and pyroptotic membrane rupture. The non-canonical pathway is triggered when cytosolic LPS activates mouse caspase-11 or human caspase-4/5, leading to GSDMD cleavage and pyroptosis, and this can secondarily activate NLRP3-dependent IL-1β release. Pyroptosis is linked to inflammatory injury, infection, cancer, liver disease, ocular disease, placental inflammation, and other disease phenotypes, but unresolved questions include which gasdermin fam
Purity & Documentation
References
[2]. Zhu J, et al. Ciliatoside A Improves Klebsiella pneumoniae-Induced Pneumonia by Modulating Mitochondrial Autophagy via the SIRT1/PINK1/Parkin Pathway. Clinical and experimental pharmacology & physiology. 2026 May;53(5):e70125. [Content Brief]
[3]. Day SH, et al. Potent cytotoxic lignans from Justicia procumbens and their effects on nitric oxide and tumor necrosis factor-alpha production in mouse macrophages. Journal of natural products. 2002 Mar;65(3):379-81. [Content Brief]
[5]. Day SH, et al. New lignan glycosides with potent antiinflammatory effect, isolated from Justicia ciliata. Journal of natural products. 2000 Nov;63(11):1560-2. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)